Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xixiai HPV egg yolk antibody gynecological gel after cervical conization in HPV-positive HSIL
ChiCTR2100045909Phase 4Recruiting
- Sponsor
- The Second Affiliated Hospital of Zhengzhou University
- Start
- Mar 2021
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in human papillomavirus infection and cervical intraepithelial neoplasia (CIN) comparing Treatment group (Xixiai gel) with Control group (observation only) (2 arms). Primary endpoints: HPV response rate at 6 months after cervical conization and HPV response rate at 12 months after cervical conization. Started Mar 2021; status: recruiting.
02
Drugs
anti-HPV egg yolk immunoglobulin
03
Conditions
human papillomavirus infectioncervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on ChiCTR2100045909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045909.